These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38593249)

  • 1. Nicotinamide in Combination with EGFR-TKIs for the Treatment of Stage IV Lung Adenocarcinoma with EGFR Mutations: A Randomized Double-Blind (Phase IIb) Trial.
    Oh HJ; Bae SC; Oh IJ; Park CK; Jung KM; Kim DM; Lee JW; Kang CK; Park IY; Kim YC
    Clin Cancer Res; 2024 Apr; 30(8):1478-1487. PubMed ID: 38593249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial.
    Li L; Jiang L; Wang Y; Zhao Y; Zhang XJ; Wu G; Zhou X; Sun J; Bai J; Ren B; Tian K; Xu Z; Xiao HL; Zhou Q; Han R; Chen H; Wang H; Yang Z; Gao C; Cai S; He Y
    Clin Cancer Res; 2019 Dec; 25(23):6967-6975. PubMed ID: 31413010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study.
    Peng P; Gong J; Zhang Y; Zhou S; Li Y; Han G; Meng R; Chen Y; Yang M; Shen Q; Chu Q; Xia S; Zhang P; Zhang L; Chen Y; Zhang L
    Radiother Oncol; 2023 Jul; 184():109681. PubMed ID: 37105304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis.
    Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M
    BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
    Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
    BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    Markóczy Z; Sárosi V; Kudaba I; Gálffy G; Turay ÜY; Demirkazik A; Purkalne G; Somfay A; Pápai-Székely Z; Rásó E; Ostoros G
    BMC Cancer; 2018 May; 18(1):598. PubMed ID: 29801465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY
    BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs.
    Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
    Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation.
    Li C; Nie W; Guo J; Xiong A; Zhong H; Chu T; Zhong R; Xu J; Lu J; Zheng X; Zhang B; Shen Y; Pan F; Han B; Zhang X
    Respir Res; 2021 May; 22(1):145. PubMed ID: 33975616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
    Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
    Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs).
    Si J; Gu X; Wang W; Ying S; Song Z
    Ann Palliat Med; 2022 May; 11(5):1624-1634. PubMed ID: 35016520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
    Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
    Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Yang S; Mao S; Li X; Zhao C; Liu Q; Yu X; Wang Y; Liu Y; Pan Y; Wang C; Gao G; Li W; Xiong A; Chen B; Sun H; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Lung Cancer; 2020 Jan; 139():133-139. PubMed ID: 31786475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.
    van Veggel B; Madeira R Santos JFV; Hashemi SMS; Paats MS; Monkhorst K; Heideman DAM; Groves M; Radonic T; Smit EF; Schuuring E; van der Wekken AJ; de Langen AJ
    Lung Cancer; 2020 Mar; 141():9-13. PubMed ID: 31926441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique.
    Gu Y; Xu Y; Zhuang H; Jiang W; Zhang H; Li X; Liu Y; Ma L; Zhao D; Cheng Y; Yu Y; Liu P; Qin J; Chen X; Gao J; Wang M; Liang L; Cao B
    Thorac Cancer; 2021 Dec; 12(23):3157-3168. PubMed ID: 34651449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
    Zhao Y; Wang S; Zhang B; Qiao R; Xu J; Zhang L; Zhang Y; Han B
    Target Oncol; 2019 Apr; 14(2):169-178. PubMed ID: 30888598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study.
    Wang Y; Yu W; Shi J; Qiu R; Jiang N; Wang Z; Yang J; Jia Z; Song M
    Technol Cancer Res Treat; 2022; 21():15330338221100358. PubMed ID: 35607295
    [No Abstract]   [Full Text] [Related]  

  • 20. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas.
    Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B
    Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.